HeXun Biosciences Cash Flow Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	131.32	147.22	33.49	-5.19	-42.99
Depreciation & Amortization	25.84	23.52	19.1	14.19	11.43
Other Amortization	1.2	1.2	1.2	0.53	0.48
Loss (Gain) From Sale of Assets	0.9	0.01	0.05	-0.02	-0.2
Stock-Based Compensation	1.18	-	-	0.3	-
Other Operating Activities	13.19	13.97	-0.07	-0.05	0.47
Change in Accounts Receivable	-7.77	-62.39	-17.3	-4.98	-
Change in Inventory	-3.96	-10.98	-4.6	-	-
Change in Accounts Payable	-3.7	1.81	-0.8	0.42	-4.3
Change in Unearned Revenue	19	6.97	-3.37	5.1	-
Change in Other Net Operating Assets	-1.72	-0.4	15.39	0.93	-0.39
Operating Cash Flow	175.46	120.92	43.09	11.23	-35.5
Operating Cash Flow Growth	162.96%	180.62%	283.77%	-	-
Capital Expenditures	-23.04	-37.29	-20.67	-1.23	-
Sale of Property, Plant & Equipment	-	-	-	0.13	8.84
Sale (Purchase) of Intangibles	-0.08	-	-0.64	-5.96	-
Investment in Securities	-158.79	-100	-	-72	-
Other Investing Activities	-	-	-3.97	-	-35.78
Investing Cash Flow	-181.91	-137.29	-25.28	-79.05	-26.95
Long-Term Debt Repaid	-	-40.31	-4.88	-2.46	-2.01
Net Debt Issued (Repaid)	-3.35	-40.31	-4.88	-2.46	-2.01
Issuance of Common Stock	-	-	125	105	78
Other Financing Activities	2.91	-	-	-	-0.2
Financing Cash Flow	-0.44	-40.31	120.12	102.54	75.79
Net Cash Flow	-6.89	-56.68	137.93	34.72	13.34
Free Cash Flow	152.42	83.63	22.42	10	-35.5
Free Cash Flow Growth	403.65%	272.98%	124.19%	-	-
Free Cash Flow Margin	50.07%	29.20%	17.17%	20.22%	-
Free Cash Flow Per Share	3.31	1.82	0.49	0.27	-1.16
Cash Interest Paid	1.24	1.24	1.79	1.64	1.57
Levered Free Cash Flow	114.42	33.7	9.68	0.46	-
Unlevered Free Cash Flow	115.09	34.43	10.84	1.48	-
Change in Working Capital	1.85	-64.99	-10.68	1.47	-4.69

Source: S&P Global Market Intelligence. Standard template. Financial Sources.